Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) produce significant, sustained weight loss in adults with obesity or overweight with comorbidities, outperforming placebo.
If lifestyle changes haven't led to sufficient weight loss, consult a doctor about GLP-1 medications like Liraglutide or Semaglutide. These are prescribed for BMI ≥ 30 (or ≥ 27 with health issues) and work by mimicking gut hormones to reduce appetite and slow digestion. Treatment is most effective when combined with diet and exercise, and must be stopped if less than 5% weight loss occurs after 12 weeks.
Liraglutid und Semaglutid sowie der neue GIP/GLP-1-Rezeptoragonist Tirzepatid haben in jüngster Zeit ihre gewichtsreduzierenden Eigenschaften unter Beweis gestellt.
Why this rating
Based on multiple Phase III randomized controlled trials (SCALE, STEP 1, SURMOUNT-1) cited in the review.
Source
Neue Behandlungsmöglichkeiten der Adipositas
Ellen Heitlinger et al. · 2024
DOI 10.36000/hbt.2023.11.001
More from this paper
- Semaglutide (2.4 mg weekly) produces greater weight loss than Liraglutide (3.0 mg daily) in patients with obesity or overweight with comorbidities.Strong
- Tirzepatide (5, 10, 15 mg weekly) produces substantial, dose-dependent weight loss in patients with obesity or overweight with comorbidities, outperforming placebo.Strong
- Bariatric surgery is the most effective, sustainable, and generally safe therapy for severe obesity (BMI ≥ 35 kg/m²) when lifestyle and pharmacological treatments have failed.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →